Division of Hematology & Thromboembolism

Sam Schulman

M.D., FRCPC(C)

Professor, Division of Hematology and Thromboembolism, Department of Medicine

Associate Professor, Medicine, Karolinska Institute, Stockholm, Sweden

Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital, Hamilton, Ontario

 

 

 

Team Members

Administrative Assistant: Heather George
Manager Anticoagulant Clinic: Marlene Robinson and Donna Carter
Clinical Trials Nurses: Michelle Zondag, Laurie Sardo
Acute Care Nurses: Thelma Mendoza, Jennifer Delaney, Joyce Colletti, Ellen Nicholson, Debra Magier, and Sandra Robinson

Education and Professional Standing

F.R.C.P.(C) Hematology, 2004
F.R.C.P.(C) Internal Medicine, 2004
Specialist, Hematology (Israel), 1993
Specialist, Coagulation and Bleeding Disorders (Sweden), 1985
Specialist, Hematology ( Sweden ), 1985
Specialist, Internal Medicine ( Sweden ), 1984

Research Interests

Dr. Schulman’s major research activities have focused on clinical studies in venous thromboembolism, including several randomized trials. The most important trials investigated the appropriate duration of secondary prophylaxis after venous thromboembolism. Dr. Schulman was also the director of a regional hemophilia treatment center in Sweden for 8 years and he has devoted another large part of his research to hemophilia, its treatment with for example continuous infusion of factor concentrates and complications of viral transmission by blood products. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors but continues the long-term track of improving treatment with vitamin K antagonists.

Dr. Schulman was chairman of the subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis 2004-2008 and is president elect for the XXV Congress of the International Society of Thrombosis and Haemostasis, Toronto 2015.

Selected Publications

  1. Schulman S, Kearon C et al. Definition of major bleeding in clinical investigations of medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
  2. The PERSIST INVESTIGATORS (Büller HR, Cohen AT, Lensing AWA, Monreal M, Prins MH, Schulman S, Lassen MR, van Amsterdam RGM). A novel long-acting synthetic factor Xa inhibitor, (SanOrg 34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
  3. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003 Oct 30;349(18):1713-21.
  4. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-83.
  5. Eriksson H, Wåhlander K, Gustafsson D, Welin L, Frison L, Schulman S. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41 -7.
  6. Schulman S, Lindmarker P and the DURAC Trial Study Group. Incidence of cancer after secondary prophylaxis against venous thromboembolism with warfarin. N Engl J Med 2000; 342: 1953-8.
  7. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
  8. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-Å, Hjorth M, Linder O, Boberg J and The DURAC Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
  9. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193